IHC Extended Panel 10 Markers: Comprehensive Cancer Biomarker Analysis
Understanding the IHC Extended Panel 10 Markers Test
The IHC Extended Panel 10 Markers represents a cutting-edge advancement in cancer diagnostics, utilizing immunohistochemistry (IHC) technology to analyze multiple protein biomarkers simultaneously. This comprehensive test provides oncologists with detailed molecular information about tumor characteristics, enabling more precise diagnosis and personalized treatment planning. By examining 10 distinct biomarkers, the test offers a complete molecular profile that goes beyond traditional single-marker testing.
What Does the Test Measure and Detect?
The IHC Extended Panel 10 Markers detects and measures specific protein expressions in tumor tissue samples, providing critical information about:
- Cancer cell type identification and classification
- Hormone receptor status (estrogen, progesterone)
- HER2/neu protein expression levels
- Proliferation markers (Ki-67)
- Angiogenesis and metastasis markers
- Drug resistance and sensitivity indicators
- Tumor suppressor protein expressions
- Cell cycle regulation markers
Who Should Consider This Test?
This comprehensive biomarker panel is recommended for patients experiencing:
- Newly diagnosed cancer requiring detailed characterization
- Complex or difficult-to-classify tumors
- Recurrent cancer requiring updated biomarker analysis
- Treatment-resistant cancers needing alternative therapy options
- Patients considering targeted therapy or immunotherapy
- Cases where standard diagnostic methods provide inconclusive results
Key Benefits of the IHC Extended Panel
Choosing the IHC Extended Panel 10 Markers offers numerous advantages:
- Comprehensive Analysis: Simultaneous evaluation of 10 biomarkers provides a complete molecular picture
- Personalized Treatment: Enables tailored therapy based on individual tumor characteristics
- Improved Accuracy: Reduces diagnostic uncertainty and misclassification
- Treatment Guidance: Identifies targeted therapy options and predicts treatment response
- Prognostic Information: Provides insights into disease progression and outcomes
Understanding Your Test Results
Your IHC Extended Panel results will include detailed information about each biomarker’s expression levels. Positive results indicate the presence of specific proteins that may influence treatment decisions. Negative results help rule out certain cancer subtypes or treatment options. Your oncologist will interpret these findings in the context of your overall clinical picture to develop the most effective treatment strategy. The comprehensive nature of this panel ensures that no critical biomarker information is overlooked.
Test Pricing and Availability
| Test Name | Discount Price | Regular Price |
|---|---|---|
| IHC Extended Panel 10 Markers | $244 USD | $326 USD |
Turnaround Time: 5 business days
Sample Type: Tissue in 10% Neutral Buffered Formalin or Paraffin Block
Nationwide Availability
We have diagnostic centers conveniently located across major US cities including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing regardless of location.
Book Your Test Today
Take control of your cancer diagnosis and treatment planning with our comprehensive IHC Extended Panel 10 Markers. Our experienced team is ready to assist you with scheduling and answer any questions about the testing process.
Call or WhatsApp: +1(267) 388-9828
Schedule your appointment today and get the detailed biomarker information needed for optimal cancer care.
Note: This test requires a doctor’s prescription. Prescription requirements do not apply to surgery and pregnancy cases or individuals planning international travel.
